Serina Therapeutics (SER) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 10, 2019
Document And Entity Information
Entity Registrant Name	AgeX Therapeutics, Inc.
Entity Central Index Key	0001708599
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		37,630,000
Trading Symbol	AGE
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 8,586	$ 6,707
Accounts and grants receivable, net	206	131
Prepaid expenses and other current assets	856	1,015
Total current assets	9,648	7,853
Equipment and furniture, net	84	90
Deposits and other long-term assets	19	19
Intangible assets, net	2,570	2,709
TOTAL ASSETS	12,321	10,671
CURRENT LIABILITIES
Accounts payable and accrued liabilities	1,316	1,366
Related party payables, net	140	132
Deferred revenues	361	317
Other current liabilities	477	625
TOTAL LIABILITIES	2,294	2,440
Commitments and contingencies (Note 8)
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of March 31, 2019 and December 31, 2018
Common stock, $0.0001 par value, 100,000 shares authorized; 37,630 and 35,830 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	4	4
Additional paid-in capital	86,480	81,499
Accumulated other comprehensive income (loss)	24	(2)
Accumulated deficit	(77,187)	(74,054)
AgeX Therapeutics, Inc. stockholders' equity	9,321	7,447
Noncontrolling interest	706	784
Total stockholders' equity	10,027	8,231
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 12,321	$ 10,671

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,630,000	35,830,000
Common stock, shares outstanding	37,630,000	35,830,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
REVENUES:
Total revenues	$ 388	$ 239
Cost of sales	(63)	(109)
Gross profit	325	130
OPERATING EXPENSES:
Research and development	(1,338)	(1,591)
Acquired in-process research and development		(800)
General and administrative	(2,109)	(1,290)
Total operating expenses	(3,447)	(3,681)
Loss from operations	(3,122)	(3,551)
OTHER INCOME/(EXPENSES):
Interest income, net	12	18
Gain on sale of equity method investment in Ascendance		3,215
Other expense, net	(28)	(3)
Total other income (expense), net	(16)	3,230
NET LOSS BEFORE INCOME TAXES	(3,138)	(321)
Income tax provision	(73)
NET LOSS	(3,211)	(321)
Net loss attributable to noncontrolling interest	78	86
NET LOSS ATTRIBUTABLE TO AGEX	$ (3,133)	$ (235)
NET LOSS PER COMMON SHARE: BASIC AND DILUTED	$ (0.09)	$ (0.01)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED	36,143,000	33,750,000
Subscription and Advertising Revenues [Member]
REVENUES:
Total revenues	$ 345	$ 239
Grant and Other Revenues [Member]
REVENUES:
Total revenues	$ 43

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
NET LOSS	$ (3,211)	$ (321)
Other comprehensive expense, net of tax:
Foreign currency translation adjustment	26	(1)
COMPREHENSIVE LOSS	(3,185)	(322)
Less: Comprehensive loss attributable to noncontrolling interest	78	86
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX	$ (3,107)	$ (236)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to AgeX	$ (3,133)	$ (235)
Net loss attributable to noncontrolling interest	(78)	(86)
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:
Gain on sale of equity method investment in Ascendance		(3,215)
Acquired in-process research and development		800
Depreciation expense	10	15
Amortization of intangible assets	139	107
Stock-based compensation	481	145
Stock-based compensation allocated from BioTime		88
Subsidiary stock-based compensation		2
Income tax provision	73
Foreign currency remeasurement loss and other	29
Changes in operating assets and liabilities:
Accounts and grants receivable, net	(75)	53
Prepaid expenses and other current assets	(64)	(29)
Accounts payable and accrued liabilities	(52)	282
Related party payables	8	(150)
Deferred revenues	44	150
Other current liabilities		68
Net cash used in operating activities	(2,618)	(2,005)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of equity method investment in Ascendance		3,215
Purchase of in-process research and development		(800)
Purchase of equipment and other	(3)	(1)
Net cash (used in) provided by investing activities	(3)	2,414
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants	4,500
Proceeds from sale of warrants		737
Net cash provided by financing activities	4,500	737
Effect of exchange rate changes on cash and cash equivalents		(1)
NET INCREASE IN CASH AND CASH EQUIVALENTS	1,879	1,145
CASH AND CASH EQUIVALENTS:
At beginning of the period	6,707	7,375
At end of the period	$ 8,586	$ 8,520

Organization, Business Overview

Organization, Business Overview and Liquidity	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Business Overview and Liquidity	1. Organization, Business Overview and Liquidity AgeX Therapeutics, Inc. (“AgeX”) was incorporated in January 2017 in the state of Delaware. Its common shares trade on the NYSE American Stock Exchange under the symbol “AGE.” AgeX , with proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, which allows it to utilize telomerase-expressing regenerative pluripotent stem cell (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX owns or has licenses to a number of patents and patent applications used in the generation of these product candidates, including intellectual property related to PSC-derived clonal progenitor cell lines ( ® technology), HyStem ® delivery matrices and (HLA-G) Technology. AgeX’s initial discovery and pre-clinical programs focus on utilizing brown adipose tissue (“brown fat”) in targeting diabetes and obesity; using AgeX’s proprietary PureStem ® . AgeX may UniverCyte (HLA-G) Technology AgeX is an “emerging growth company” as defined in the Jumpstart our Business Startups Act of 2012. On June 7, 2018, AgeX sold 2.0 million shares of common stock to Juvenescence Limited (“Juvenescence”) for $2.50 per share for aggregate cash proceeds to AgeX of $5.0 million. BioTime’s sale of significant ownership interest in AgeX to Juvenescence as a subsidiary of BioTime, Inc. (“BioTime”), a publicly-traded, clinical-stage biotechnology company. As a result of the sale of AgeX shares to Juvenescence by BioTime, on August 30, 2018, AgeX ceased to be a subsidiary of BioTime because on that date, BioTime experienced a “loss of control” of a subsidiary, as defined by generally accepted accounting principles in the U.S. (“GAAP”). Loss of control is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock in the subsidiary, lacks a controlling financial interest in the subsidiary and, is unable to unilaterally control the subsidiary through other means such as having, or being able to obtain, the power to elect a majority of the subsidiary’s Board of Directors based solely on contractual rights or ownership of shares holding a majority of the voting power of the subsidiary’s voting securities. All of these loss-of-control factors were present with respect to BioTime’s ownership interest in AgeX as of August 30, 2018. On November 28, 2018 (the “Distribution Date”), BioTime owned 14,416,000 shares of AgeX common stock, representing approximately 40.2% of the shares of the common stock issued and outstanding on the Distribution Date. On the Distribution Date, BioTime distributed to its shareholders, on a pro rata basis, 12,697,028 shares of the AgeX common stock it then held (the “Distribution”). Immediately after the Distribution, BioTime retained 1,718,972 shares of AgeX common stock, representing approximately 4.8% of the common stock then issued and outstanding. Following the Distribution, AgeX common stock began publicly trading on the NYSE American under the symbol “AGE”. Juvenescence is currently AgeX’s largest shareholder holding approximately 44% of AgeX’s issued and outstanding shares of common stock as of March 31, 2019. Liquidity Since inception, AgeX has financed its operations through contributions and advances from its former parent company, BioTime, the sale of its common stock and warrants, exercises of warrants, and research grants. BioTime has also provided AgeX with the use of BioTime facilities and services under a Shared Facilities and Services Agreement as described in Note 4. Although BioTime may continue to provide administrative support to AgeX on a reimbursable basis, AgeX does not expect BioTime to provide future financing. AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $77.2 million as of March 31, 2019. AgeX expects to continue to incur operating losses and negative cash flows. Based on its cash and cash equivalents as of March 31, 2019, AgeX has made certain adjustments to its operating plans and budgets to reduce its projected cash expenditures in order to extend the period over which it can continue its operations with its available cash resources. Some of these adjustments will entail the deferral of certain work on the development of AgeX’s product candidates and technologies, which is likely to delay progress in those research and development efforts. Based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $8.6 million as of March 31, 2019 provide sufficient cash, cash equivalents, and liquidity to carry out AgeX’s operations through at least twelve months from the issuance date of the consolidated financial statements included herein.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements at that date, but does not include all the information and footnotes required by GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2018. The accompanying condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of AgeX’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. For periods prior to August 30, 2018, To the extent AgeX does not have its own employees, human resources or facilities for its operations, BioTime or BioTime commonly controlled and consolidated subsidiaries provide certain employees for administrative or operational services, including laboratory space and administrative facilities, as necessary, for the benefit of AgeX, under a Shared Facilities and Services Agreement (the “Shared Facilities Agreement”) with BioTime (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of AgeX based on the amount of time that particular employees devote to AgeX affairs. Other expenses such as legal, accounting and financial reporting, marketing, and travel expenses are allocated to AgeX to the extent that those expenses are incurred by or on behalf of AgeX. BioTime also allocates certain overhead expenses such as rent and utilities, property taxes, insurance, laboratory expenses and supplies, telecommunications and other indirect expenses. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, headcount and percentage of personnel devoted to AgeX’s operations or management. Management evaluates the appropriateness of the allocations on a periodic basis and believes that this basis for allocation is reasonable. Juvenescence also provides the services of certain of its employees to AgeX on a cost reimbursement basis. See Note 4. Principles of consolidation AgeX’s condensed consolidated interim financial statements include the accounts of its subsidiaries. The following table reflects AgeX’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of March 31, 2019. Subsidiary Field of Business AgeX Ownership Country ReCyte Therapeutics Early stage pre-clinical research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity 94.8 % USA LifeMap Sciences (1) Biomedical, gene, and disease databases and tools 81.7 % USA (1) LifeMap Sciences includes LifeMap Sciences, Inc. and its wholly-owned subsidiary LifeMap Sciences, Ltd. an Israeli company. All material intercompany accounts and transactions have been eliminated in consolidation. As of March 31, 2019, AgeX consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholders’ equity on AgeX’s consolidated balance sheets. Revenue recognition During the first quarter of 2018, AgeX adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASU 2014-09, Revenues from Contracts with Customers (Topic 606) AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. Subscription and advertising revenues GeneCards ® GeneCards ® MalaCards LifeMap Sciences’ performance obligations for subscriptions include a license of intellectual property related to its genetic information packages and premium genetic information tools. These licenses are deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. Payments are typically received at the beginning of a subscription period and revenue is recognized according to the type of subscription sold. For subscription contracts in which the subscription term commences before a payment is due, LifeMap Sciences records an accounts receivable as the subscription is earned over time and bills the customer according to the contract terms. LifeMap Sciences continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the allowance for doubtful accounts. LifeMap Sciences has not historically provided significant discounts, credits, concessions, or other incentives from the stated price in the contract as the prices are offered on a fixed fee basis for the type of subscription package being purchased. LifeMap Sciences may issue refunds only if the packages cease to be available for reasons beyond its control. In such an event, the customer will get a refund on a pro-rata basis. Both the customer and LifeMap Sciences expect the subscription packages to be available during the entire subscription period, and LifeMap Sciences has not experienced any significant issues with the availability of the product and has not issued any material refunds. Using the most likely amount method for estimating refunds under Topic 606, including historical experience, LifeMap Sciences determined that the single most likely amount of variable consideration for refunds is immaterial as LifeMap Sciences does not expect to pay any refunds. LifeMap Sciences performance obligations for advertising are overall advertising services and represent a series of distinct services. Contracts are typically less than a year in duration and the fees charged may include a combination of fixed and variable fees with the variable fees tied to click throughs to the customer’s products on their website. LifeMap Sciences allocates the variable consideration to each month the click through services occur and allocates the annual fee to the performance obligation period of the initial term of the contract because those amounts correspond to the value provided to the customer each month. For click-through advertising services, at the time the variable compensation is known and determinable, the service has been rendered. Revenue is recognized at that time. The annual fee is recognized over the initial subscription period because this is a service and the customer simultaneously receives and consumes the benefit of LifeMap Sciences’ performance. LifeMap Sciences deferred subscription revenues primarily represent subscriptions for which cash payment has been received for the subscription term, but the subscription term has not been completed as of the balance sheet date. For the three months ended March 31, 2019 and 2018, LifeMap Sciences recognized $345,000 and $239,000, respectively, in subscription and advertising revenues. As of March 31, 2019, there was $361,000 included in deferred revenues in the consolidated balance sheets which is expected to be recognized as subscription revenue over the next twelve months. LifeMap Sciences has licensed from third parties the databases and software it commercializes and has a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs are included in cost of sales on the condensed consolidated statements of operations when the cash is received, and the royalty obligation is incurred as the royalty payments do not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers Grant revenues Research and Development Arrangements In September 2018, AgeX was awarded a grant of up to approximately $225,000 from the National Institutes of Health (NIH). The NIH grant provides funding for continued development of AgeX technologies for treating osteoporosis. The grant funds will be made available by the NIH as allowable expenses are incurred. For the three months ended March 31, 2019, AgeX incurred approximately $15,000 of allowable expenses under the NIH grant and recognized a corresponding amount of . AgeX had no grant revenues for the three months ended March 31, 2018. Research and development Research and development expenses include both direct expenses incurred by AgeX or its subsidiaries and indirect overhead costs allocated by BioTime that benefit or support AgeX’s research and development functions. Direct research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Indirect research and development expenses allocated by BioTime to AgeX under the Shared Facilities Agreement (see Note 4), are primarily based on headcount or space occupied, as applicable, and include laboratory supplies, laboratory expenses, rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies, including service revenues from co-development projects with customers, if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations. General and administrative General and administrative expenses include both direct expenses incurred by AgeX and indirect overhead costs allocated by BioTime that benefit or support AgeX’s general and administrative functions. Direct general and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Indirect general and administrative expenses allocated by BioTime to AgeX under the Shared Facilities Agreement (see Note 4) are primarily based on headcount or space occupied, as applicable, and include costs for financial reporting and compliance, rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Basic and diluted net loss per share attributable to common stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common shares outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under outstanding stock options and warrants, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method . For the three months ended March 31, 2019 and 2018, b The following weighted average common stock equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Stock options 2,401 1,302 Warrants (1) - 1,474 Restricted stock units 12 - (1) The warrants were either exercised or expired on March 18, 2019 (see Note 5). Recently adopted accounting pronouncements Leases On January 1, 2019, AgeX adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted improvements, AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensed consolidated balance sheet. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Upon adoption of ASC 842 and based on the practical expedients available under that standard, AgeX did not reassess any expired or existing contracts, reassess the lease classification for any expired or existing leases and reassess initial direct costs for exiting leases. AgeX also elected not to capitalize leases that have terms of twelve months or less. The adoption of ASC 842 had no impact on AgeX’s consolidated balance sheets as AgeX did not have operating leases as of March 31, 2019 and December 31, 2018 (see Note 4). AgeX’s new sublease discussed in Note 9, which commenced on April 2, 2019, will be subject to ASC 842 and AgeX will recognize this lease as a right-of-use asset and operating lease liability on its balance sheet in accordance with ASC 842 in the second quarter of 2019. Stock-based compensation In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Reclassifications A reclassification was made from amounts included in accounts payable and accrued liabilities to related party payables, net, on the condensed consolidated balance sheet as of December 31, 2018 to conform and be comparable to the presentation on the condensed consolidated balance sheet as of March 31, 2019. The reclassification had no impact to the condensed consolidated financial statements for any period presented. Recently issued accounting pronouncements not yet adopted The recently issued accounting pronouncements applicable to AgeX that are not yet effective should be read in conjunction with the recently issued accounting pronouncements, as applicable and disclosed in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2018. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement

Selected Balance Sheet Componen

Selected Balance Sheet Components	3 Months Ended
	Mar. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Selected Balance Sheet Components	3. Selected Balance Sheet Components Intangible assets, net As of March 31, 2019 and December 31, 2018, intangible assets, primarily consisting of acquired in-process research and development and patents, and accumulated amortization were as follows (in thousands): March 31, 2019 (unaudited) December 31, 2018 Intangible assets $ 5,586 $ 5,586 Accumulated amortization (3,016 ) (2,877 ) Total intangible assets, net $ 2,570 $ 2,709 AgeX recognized $139,000 and $107,000 in amortization expense of intangible assets, included in research and development expenses, for the three months ended March 31, 2019 and 2018, respectively. Accounts payable and accrued liabilities As of March 31, 2019 and December 31, 2018, accounts payable and accrued liabilities were comprised of the following (in thousands): March 31, 2019 (unaudited) December 31, 2018 Accounts payable $ 272 $ 150 Accrued compensation 298 254 Accrued vendors and other expenses 746 962 Total accounts payable and accrued liabilities $ 1,316 $ 1,366

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions Shared Facilities and Service Agreement On August 17, 2017, AgeX and BioTime executed the Shared Facilities Agreement. Under the terms of the Shared Facilities Agreement, BioTime agrees to permit AgeX to use its premises and equipment located at Alameda, California for the purpose of conducting business. BioTime will also provide accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to AgeX. BioTime may also provide the services of attorneys, accountants, and other professionals who may also provide professional services to BioTime and its other subsidiaries. BioTime may also provide AgeX with the services of its laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for AgeX at the premises. BioTime charges AgeX a “Use Fee” for services received and usage of facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates as a Use Fee costs incurred, as applicable, to AgeX. Such costs generally include services of BioTime employees, consultants, and contractors; equipment use, insurance, lease expense, fees for services of accountants, lawyers, and other professionals; software; supplies; and utilities. Allocation depends on key cost drivers including actual documented use, square footage of facilities used, time spent, costs incurred by or for AgeX, or upon proportionate usage by BioTime and AgeX, as reasonably estimated by BioTime. BioTime, at its discretion, has the right to charge AgeX a 5% markup on such allocated costs and BioTime has charged this markup since the August 17, 2017 inception of the Shared Facilities Agreement with AgeX. The allocated cost of BioTime employees and contractors who provide services is based upon records maintained of the number of hours or percentage of time of such personnel devoted to the performance of services. The Use Fee is determined and invoiced to AgeX on a monthly basis for each calendar month of each calendar year. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by AgeX within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from AgeX funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of AgeX. To date BioTime has not charged AgeX any interest. In addition to the Use Fees, AgeX will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of AgeX, provided that invoices documenting such costs are delivered to AgeX with each invoice for the Use Fee. Furthermore, BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for AgeX, and if any such supplies, goods, materials or services are obtained for AgeX, BioTime may arrange for the suppliers thereof to invoice AgeX directly. The Shared Facilities Agreement will remain in effect from year to year, unless either party gives the other party written six months’ notice to terminate, which BioTime may not give to AgeX prior to September 1, 2020, or unless the agreement is otherwise terminated under another provision of the agreement. The Shared Facilities Agreement is not considered a lease under the provisions of ASC 842 discussed in Note 2, because, among other factors, a significant part of the Shared Facilities Agreement is a contract for services, not a tangible asset, and is cancelable by either party without penalty. See Note 9 for discussion of AgeX’s new sublease that commenced on April 2, 2019, and AgeX’s notice to BioTime on May 7, 2019 regarding the termination of the facilities portion of the Shared Facilities Agreement. In aggregate, BioTime charged such Use Fees to AgeX and subsidiaries as follows : Three Months Ended March 31, (unaudited) 2019 2018 Research and development $ 286 $ 318 General and administrative 114 70 Total Use Fees $ 400 $ 388 AgeX accounts for payables to an affiliate, net of receivables from that affiliate, if any, for shared services and other transactions that AgeX may enter into with that affiliate. AgeX records those payables and receivables on a net basis since AgeX and the affiliate intends to exercise a right of offset of the payable and the receivable and to settle the balances net by having the party that owes the other party pay the net balance owed AgeX had $16,000 in related party receivables from BioTime and $34,000 in related party payables due to BioTime, included in related party payables, net, on the condensed consolidated balance sheets as of March 31, 2019 and December 31, 2018, respectively. Transactions with Juvenescence Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, is devoting a majority of his time to AgeX’s operations for which AgeX reimburses Juvenescence for his services on an agreed upon annual amount of approximately $273,000 (annual amount allocated to AgeX by Juvenescence). As of March 31, 2019 and December 31, 2018, AgeX had approximately $156,000 and $98,000, respectively, payable to Juvenescence for COO services rendered, included in related party payables, net, on the condensed consolidated balance sheets (see Note 9). Transactions with Ascendance On March 21, 2018, AgeX and Ascendance entered into an Asset Purchase Agreement (the “Asset Agreement”) in which AgeX purchased for $800,000 in cash certain assets consisting in value primarily of in-process research and development assets related to stem cell derived cardiomyocytes (heart muscle cells) to be developed by AgeX. The transaction was considered an asset acquisition rather than a business combination in accordance with ASC 805-50. The $800,000 purchase price was expensed on the acquisition date as acquired in-process research and development in accordance with as those assets have no alternative future uses. Disposition of ownership interest in Ascendance On March 23, 2018, Ascendance was acquired by a third party in a merger through which AgeX received approximately $3.2 million in cash for its shares of Ascendance common stock. AgeX recognized a $3.2 million gain on sale of its equity method investment in Ascendance, which is included in other income and expenses, net, for the three months ended March 31, 2018. At the close of the merger, $955,000 of cash that otherwise would have been payable to the Ascendance stockholders was deposited into an escrow account where it may be held for a term of up to fifteen months. Funds held in the escrow account may be paid to the acquirer to cover indemnity payments and other obligations that may arise after the merger. After the expiration of the term of the escrow, any funds remaining in the escrow account will be disbursed, on a pro-rata basis, to the former Ascendance stockholders. As of March 31, 2019, no amounts have been recorded in the AgeX condensed consolidated interim financial statements for any funds held in the escrow account. Sale and exercise of AgeX warrants In February 2018, AgeX sold warrants, as described in Note 5, to certain investors, including to

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Stockholders' Equity	5. Stockholders’ Equity Preferred Stock AgeX is authorized to issue up to 5,000,000 shares of $0.0001 par value preferred stock. To date, no preferred shares are issued and outstanding. Common Stock AgeX has up to 100,000,000 shares of $0.0001 par value common stock authorized. See Note 4 for related party transactions with BioTime that impacted AgeX’s condensed consolidated statements of stockholders’ equity. On February 28, 2018, AgeX sold warrants to purchase 1,473,600 shares of AgeX common stock (the “Warrants”) for $0.50 per warrant for aggregate cash proceeds to AgeX of $736,800. On July 10, 2018, AgeX sold additional Warrants to purchase 526,400 shares of common stock for $0.50 per warrant for aggregate net cash proceeds to AgeX of $263,200. The Warrants were exercisable at $2.50 per share. On March 18, 2019, holders of the Warrants purchased a total of 1,800,000 shares of AgeX common stock through the exercise of Warrants at an exercise price of $2.50 per share, for total proceeds to AgeX of $4.5 million. Any unexercised Warrants expired on that date. As of March 31, 2019 and December 31, 2018, there were 37,630,000 and 35,830,000 shares of AgeX common stock issued and outstanding, respectively. Reconciliation of Changes in Stockholders’ Equity The following tables provide the activity in AgeX’s consolidated stockholders’ equity for the periods from December 31, 2017 to March 31, 2018 and December 31, 2018 to March 31, 2019 (unaudited and in thousands). Common Stock Additional Accumulated Other Total Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income/ (Loss) Stockholders’ Equity BALANCE AT DECEMBER 31, 2017 33,750 $ 3 $ 73,761 $ (66,552 ) $ 1,039 $ 68 $ 8,319 Sale of warrants - - 737 - - - 737 Stock-based compensation - - 145 - - - 145 Stock-based compensation allocated from BioTime - - 88 - - - 88 Stock-based compensation in subsidiaries - - - - 2 - 2 Foreign currency translation adjustment - - - - - (1 ) (1 ) Net loss - - - (235 ) (86 ) - (321 ) BALANCE AT MARCH 31, 2018 33,750 $ 3 $ 74,731 $ (66,787 ) $ 955 $ 67 $ 8,969 Common Stock Additional Accumulated Other Total Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income/ (Loss) Stockholders’ Equity BALANCE AT DECEMBER 31, 2018 35,830 $ 4 $ 81,499 $ (74,054 ) $ 784 $ (2 ) $ 8,231 Issuance of common stock from exercise of warrants 1,800 - 4,500 - - - 4,500 Stock-based compensation - - 481 - - - 481 Foreign currency translation adjustment - - - - - 26 26 Net loss - - - (3,133 ) (78 ) (3,211 ) BALANCE AT MARCH 31, 2019 37,630 $ 4 $ 86,480 $ (77,187 ) $ 706 $ 24 $ 10,027

Stock-Based Awards

Stock-Based Awards	3 Months Ended
	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Awards	6. Stock-Based Awards Equity Incentive Plan Awards AgeX adopted its 2017 Equity Incentive Plan (the “Plan”) under which a maximum of 4,000,000 shares of common stock are available for the grant of stock options, the sale of restricted stock, the settlement of restricted stock units, and the grant of stock appreciation rights. The Plan also permits AgeX to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine. On March 11, 2019, AgeX granted 50,000 restricted stock units and stock options to purchase 600,000 shares of common stock with an exercise price of $4.28 to its employees, directors and a consultant under the Plan. These grants are subject to customary vesting terms and conditions in accordance with the Plan. A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price December 31, 2018 1,731 2,269 - $ 2.42 Restricted stock units granted (100 ) - 50 - Options granted (567 ) 567 - 4.28 Options exercised - - - - Options forfeited/cancelled - - - - March 31, 2019 1,064 2,836 50 $ 2.79 Options exercisable at March 31, 2019 949 $ 2.22 Stock-based Compensation Expense The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions noted in the following table Three Months Ended March 31, (unaudited) 2019 2018 Expected life (in years) 5.7 6.02 Risk-free interest rates 2.44 % 2.67 % Volatility 78.45 % 74.65 % Dividend yield - % - % Operating expenses include stock-based compensation expense as follows (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Research and development $ 27 $ 51 General and administrative 454 184 Total stock-based compensation expense $ 481 $ 235

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. On March 23, 2018, Ascendance was acquired by a third party in a merger through which AgeX received approximately $3.2 million in cash for its shares of Ascendance common stock. For financial reporting purposes, AgeX recognized a $3.2 million gain on the sale of its equity method investment in Ascendance (see Note 4). The sale was a taxable transaction to AgeX generating a taxable gain of approximately $2.2 million. AgeX has sufficient current year losses from operations to offset the entire gain resulting in no income taxes due. As further discussed in Note 1, on August 30, 2018, BioTime consummated the sale of 14,400,000 shares of common stock of AgeX owned by BioTime to Juvenescence. AgeX received no proceeds from that transaction. Prior to the transaction, Juvenescence owned 5.6% of AgeX’s issued and outstanding common stock. Upon completion of the transaction, BioTime’s ownership in AgeX was reduced from 80.4% to 40.2% of AgeX’s issued and outstanding shares of common stock, and Juvenescence’s ownership in AgeX was increased from 5.6% to 45.8% of AgeX’s issued and outstanding shares of common stock. Accordingly, beginning on August 31, 2018, AgeX will no longer be included in BioTime’s consolidated federal and state income tax returns as AgeX will file its own, standalone returns with its subsidiaries. Beginning in 2018, the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”), subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2018, AgeX included an immaterial amount of GILTI in U.S. gross income related to LifeMap Sciences, Ltd., which was fully offset by operating losses. For the three months ended March 31, 2019, AgeX’s foreign income inclusion was less than the deemed return on tangible assets, therefore no GILTI was included in income for the first quarter of 2019. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. AgeX has elected to account for GILTI as a current period expense when incurred. For the period ended March 31, 2019, AgeX generated a domestic loss from continuing operations but generated foreign income attributable primarily to foreign currency transaction gains for the current period. This foreign income was principally related to the remeasurement of the U.S. dollar denominated intercompany advances payable by LifeMap Sciences, Ltd. to LifeMap Sciences, Inc., for which a foreign income tax provision of $73,000 was recorded for the three months ended March 31, 2019. Due to losses incurred for all periods presented, AgeX did not record a domestic provision or benefit for income taxes. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all of its domestic deferred tax assets for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies At March 31, 2019, AgeX had no commitments other than those under the Shared Facilities Agreement described in Note 4. The minimum fixed payments due under the Shared Facilities Agreement are approximately $133,333 per month (see Note 9). Litigation – General AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. Employment Contracts AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations related to certain terminations of employment. Indemnification In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s pre-clinical programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s pre-clinical programs. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to AgeX’s pre-clinical programs. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements as of March 31, 2019 and December 31, 2018.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events Lease Agreement On April 2, 2019, the term of a sublease that AgeX entered into during March 2019 went into effect for an office and research facility (the “New Facility”) comprising approximately 23,911 square feet of space in a building in an office and research park at 965 Atlantic Avenue, Alameda, California. AgeX plans to operate its principal offices and research laboratory at the New Facility. Base monthly rent is $35,866.50 for the initial 12 months of the sublease term and then will increase to $36,942.50. In addition, AgeX will pay real property taxes, insurance and operating expenses pertaining to the building in which the New Facility is located. The sublease term will expire on December 31, 2020. AgeX will be responsible for the maintenance and repair of the New Facility, including electrical, plumbing, HVAC and other systems serving the New Facility but excluding structural and other external portions of the building in which the New Facility is located, and other external areas such as parking, landscaping and walkways associated with the building. AgeX will be in default under the sublease, and the sublandlord may terminate the sublease and may exercise other remedies against AgeX for losses and damages under the sublease and applicable law, if any one or more of the following events occurs: (a) AgeX fails to pay any rent or any other sum required to be paid under the sublease for a period of ten (10) days after written notice of delinquency is delivered by the sublandlord; provided, however, that if AgeX fails to pay rent or other sums due within ten (10) days of the date due three or more times during any twelve month period, then any subsequent failure to pay any rent or other sum when due shall constitute a default without the requirement of any written notice; (b) a material default by AgeX in the performance of any other terms, covenants or conditions of the sublease where the failure continues for thirty (30) days after written notice from the sublandlord; provided that if AgeX defaults in the performance of the same obligation three or more times in any twelve month period and notice from the sublandlord was given in each instance, no cure period shall thereafter be applicable; (c) AgeX becomes bankrupt or insolvent, makes an assignment for the benefit of creditors, bankruptcy or reorganization proceedings are commenced by or against AgeX, and in the case of an involuntary proceeding are not discharged within 60 days, the appointment of a receiver for a substantial part of AgeX’s assets, or the levy upon the sublease or AgeX’s estate in the sublease by attachment or execution, or (d) AgeX abandons the New Facility. AgeX has agreed to indemnify the sublandlord against certain liabilities arising under laws pertaining to hazardous materials. The indemnity of the sublandlord will pertain to any deposit, spill, discharge or release of hazardous materials that occurs during the term of the sublease or from AgeX’s failure to comply with requirements of governmental authorities. The sublease requires AgeX to maintain certain liability and other insurance and contains customary provisions pertaining to matters such as damage or destruction of the New Facility, taking by eminent domain or similar process, restrictions on subletting and assignment, and other matters. In connection with the sublease, AgeX also purchased certain laboratory and other equipment from the sublessor for $35,000. Notice of termination of Shared Facilities Agreement On May 7, 2019, AgeX provided written notice that it will terminate its use of BioTime’s office and laboratory facilities as of July 31, 2019. The other provisions of the Shared Facilities Agreement remain in place at this time.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of consolidation AgeX’s condensed consolidated interim financial statements include the accounts of its subsidiaries. The following table reflects AgeX’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of March 31, 2019. Subsidiary Field of Business AgeX Ownership Country ReCyte Therapeutics Early stage pre-clinical research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity 94.8 % USA LifeMap Sciences (1) Biomedical, gene, and disease databases and tools 81.7 % USA (1) LifeMap Sciences includes LifeMap Sciences, Inc. and its wholly-owned subsidiary LifeMap Sciences, Ltd. an Israeli company. All material intercompany accounts and transactions have been eliminated in consolidation. As of March 31, 2019, AgeX consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholders’ equity on AgeX’s consolidated balance sheets.
Revenue Recognition	Revenue recognition During the first quarter of 2018, AgeX adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASU 2014-09, Revenues from Contracts with Customers (Topic 606) AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. Subscription and advertising revenues GeneCards ® GeneCards ® MalaCards LifeMap Sciences’ performance obligations for subscriptions include a license of intellectual property related to its genetic information packages and premium genetic information tools. These licenses are deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. Payments are typically received at the beginning of a subscription period and revenue is recognized according to the type of subscription sold. For subscription contracts in which the subscription term commences before a payment is due, LifeMap Sciences records an accounts receivable as the subscription is earned over time and bills the customer according to the contract terms. LifeMap Sciences continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the allowance for doubtful accounts. LifeMap Sciences has not historically provided significant discounts, credits, concessions, or other incentives from the stated price in the contract as the prices are offered on a fixed fee basis for the type of subscription package being purchased. LifeMap Sciences may issue refunds only if the packages cease to be available for reasons beyond its control. In such an event, the customer will get a refund on a pro-rata basis. Both the customer and LifeMap Sciences expect the subscription packages to be available during the entire subscription period, and LifeMap Sciences has not experienced any significant issues with the availability of the product and has not issued any material refunds. Using the most likely amount method for estimating refunds under Topic 606, including historical experience, LifeMap Sciences determined that the single most likely amount of variable consideration for refunds is immaterial as LifeMap Sciences does not expect to pay any refunds. LifeMap Sciences performance obligations for advertising are overall advertising services and represent a series of distinct services. Contracts are typically less than a year in duration and the fees charged may include a combination of fixed and variable fees with the variable fees tied to click throughs to the customer’s products on their website. LifeMap Sciences allocates the variable consideration to each month the click through services occur and allocates the annual fee to the performance obligation period of the initial term of the contract because those amounts correspond to the value provided to the customer each month. For click-through advertising services, at the time the variable compensation is known and determinable, the service has been rendered. Revenue is recognized at that time. The annual fee is recognized over the initial subscription period because this is a service and the customer simultaneously receives and consumes the benefit of LifeMap Sciences’ performance. LifeMap Sciences deferred subscription revenues primarily represent subscriptions for which cash payment has been received for the subscription term, but the subscription term has not been completed as of the balance sheet date. For the three months ended March 31, 2019 and 2018, LifeMap Sciences recognized $345,000 and $239,000, respectively, in subscription and advertising revenues. As of March 31, 2019, there was $361,000 included in deferred revenues in the consolidated balance sheets which is expected to be recognized as subscription revenue over the next twelve months. LifeMap Sciences has licensed from third parties the databases and software it commercializes and has a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs are included in cost of sales on the condensed consolidated statements of operations when the cash is received, and the royalty obligation is incurred as the royalty payments do not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers Grant revenues Research and Development Arrangements In September 2018, AgeX was awarded a grant of up to approximately $225,000 from the National Institutes of Health (NIH). The NIH grant provides funding for continued development of AgeX technologies for treating osteoporosis. The grant funds will be made available by the NIH as allowable expenses are incurred. For the three months ended March 31, 2019, AgeX incurred approximately $15,000 of allowable expenses under the NIH grant and recognized a corresponding amount of . AgeX had no grant revenues for the three months ended March 31, 2018.
Research and Development	Research and development Research and development expenses include both direct expenses incurred by AgeX or its subsidiaries and indirect overhead costs allocated by BioTime that benefit or support AgeX’s research and development functions. Direct research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Indirect research and development expenses allocated by BioTime to AgeX under the Shared Facilities Agreement (see Note 4), are primarily based on headcount or space occupied, as applicable, and include laboratory supplies, laboratory expenses, rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies, including service revenues from co-development projects with customers, if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations.
General and Administrative	General and administrative General and administrative expenses include both direct expenses incurred by AgeX and indirect overhead costs allocated by BioTime that benefit or support AgeX’s general and administrative functions. Direct general and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Indirect general and administrative expenses allocated by BioTime to AgeX under the Shared Facilities Agreement (see Note 4) are primarily based on headcount or space occupied, as applicable, and include costs for financial reporting and compliance, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.
Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	Basic and diluted net loss per share attributable to common stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common shares outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under outstanding stock options and warrants, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method . For the three months ended March 31, 2019 and 2018, b The following weighted average common stock equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Stock options 2,401 1,302 Warrants (1) - 1,474 Restricted stock units 12 - (1) The warrants were either exercised or expired on March 18, 2019 (see Note 5).
Recently Adopted Accounting Pronouncements	Recently adopted accounting pronouncements Leases On January 1, 2019, AgeX adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted improvements, AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensed consolidated balance sheet. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Upon adoption of ASC 842 and based on the practical expedients available under that standard, AgeX did not reassess any expired or existing contracts, reassess the lease classification for any expired or existing leases and reassess initial direct costs for exiting leases. AgeX also elected not to capitalize leases that have terms of twelve months or less. The adoption of ASC 842 had no impact on AgeX’s consolidated balance sheets as AgeX did not have operating leases as of March 31, 2019 and December 31, 2018 (see Note 4). AgeX’s new sublease discussed in Note 9, which commenced on April 2, 2019, will be subject to ASC 842 and AgeX will recognize this lease as a right-of-use asset and operating lease liability on its balance sheet in accordance with ASC 842 in the second quarter of 2019. Stock-based compensation In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting
Reclassifications	Reclassifications A reclassification was made from amounts included in accounts payable and accrued liabilities to related party payables, net, on the condensed consolidated balance sheet as of December 31, 2018 to conform and be comparable to the presentation on the condensed consolidated balance sheet as of March 31, 2019. The reclassification had no impact to the condensed consolidated financial statements for any period presented.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently issued accounting pronouncements not yet adopted The recently issued accounting pronouncements applicable to AgeX that are not yet effective should be read in conjunction with the recently issued accounting pronouncements, as applicable and disclosed in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2018. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of Ownership of Outstanding Shares of Its Subsidiaries	The following table reflects AgeX’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of March 31, 2019. Subsidiary Field of Business AgeX Ownership Country ReCyte Therapeutics Early stage pre-clinical research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity 94.8 % USA LifeMap Sciences (1) Biomedical, gene, and disease databases and tools 81.7 % USA (1) LifeMap Sciences includes LifeMap Sciences, Inc. and its wholly-owned subsidiary LifeMap Sciences, Ltd. an Israeli company.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following weighted average common stock equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Stock options 2,401 1,302 Warrants (1) - 1,474 Restricted stock units 12 - (1) The warrants were either exercised or expired on March 18, 2019 (see Note 5).

Selected Balance Sheet Compon_2

Selected Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Schedule of Intangible Assets, Net	As of March 31, 2019 and December 31, 2018, intangible assets, primarily consisting of acquired in-process research and development and patents, and accumulated amortization were as follows (in thousands): March 31, 2019 (unaudited) December 31, 2018 Intangible assets $ 5,586 $ 5,586 Accumulated amortization (3,016 ) (2,877 ) Total intangible assets, net $ 2,570 $ 2,709
Schedule of Accounts Payable and Accrued Liabilities	As of March 31, 2019 and December 31, 2018, accounts payable and accrued liabilities were comprised of the following (in thousands): March 31, 2019 (unaudited) December 31, 2018 Accounts payable $ 272 $ 150 Accrued compensation 298 254 Accrued vendors and other expenses 746 962 Total accounts payable and accrued liabilities $ 1,316 $ 1,366

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	In aggregate, BioTime charged such Use Fees to AgeX and subsidiaries as follows : Three Months Ended March 31, (unaudited) 2019 2018 Research and development $ 286 $ 318 General and administrative 114 70 Total Use Fees $ 400 $ 388

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Summary of Reconciliation Changes in Stockholders' Equity	The following tables provide the activity in AgeX’s consolidated stockholders’ equity for the periods from December 31, 2017 to March 31, 2018 and December 31, 2018 to March 31, 2019 (unaudited and in thousands). Common Stock Additional Accumulated Other Total Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income/ (Loss) Stockholders’ Equity BALANCE AT DECEMBER 31, 2017 33,750 $ 3 $ 73,761 $ (66,552 ) $ 1,039 $ 68 $ 8,319 Sale of warrants - - 737 - - - 737 Stock-based compensation - - 145 - - - 145 Stock-based compensation allocated from BioTime - - 88 - - - 88 Stock-based compensation in subsidiaries - - - - 2 - 2 Foreign currency translation adjustment - - - - - (1 ) (1 ) Net loss - - - (235 ) (86 ) - (321 ) BALANCE AT MARCH 31, 2018 33,750 $ 3 $ 74,731 $ (66,787 ) $ 955 $ 67 $ 8,969 Common Stock Additional Accumulated Other Total Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income/ (Loss) Stockholders’ Equity BALANCE AT DECEMBER 31, 2018 35,830 $ 4 $ 81,499 $ (74,054 ) $ 784 $ (2 ) $ 8,231 Issuance of common stock from exercise of warrants 1,800 - 4,500 - - - 4,500 Stock-based compensation - - 481 - - - 481 Foreign currency translation adjustment - - - - - 26 26 Net loss - - - (3,133 ) (78 ) (3,211 ) BALANCE AT MARCH 31, 2019 37,630 $ 4 $ 86,480 $ (77,187 ) $ 706 $ 24 $ 10,027

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	3 Months Ended
	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price December 31, 2018 1,731 2,269 - $ 2.42 Restricted stock units granted (100 ) - 50 - Options granted (567 ) 567 - 4.28 Options exercised - - - - Options forfeited/cancelled - - - - March 31, 2019 1,064 2,836 50 $ 2.79 Options exercisable at March 31, 2019 949 $ 2.22
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options	The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions noted in the following table Three Months Ended March 31, (unaudited) 2019 2018 Expected life (in years) 5.7 6.02 Risk-free interest rates 2.44 % 2.67 % Volatility 78.45 % 74.65 % Dividend yield - % - %
Schedule of Stock Based Compensation Expense	Operating expenses include stock-based compensation expense as follows (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Research and development $ 27 $ 51 General and administrative 454 184 Total stock-based compensation expense $ 481 $ 235

Organization, Business Overvi_2

Organization, Business Overview and Liquidity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Nov. 28, 2018	Aug. 30, 2018	Jun. 07, 2018	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Accumulated deficit				$ (77,187)	$ (74,054)
Cash and cash equivalents				$ 8,586	$ 6,707	$ 8,520	$ 7,375
Juvenescence [Member]
Ownership interest				44.00%
BioTime [Member]
Ownership interest		40.20%
Percentage of ownership before transaction		80.40%
Percentage of ownership after transaction		40.20%
Common Stock [Member]
Ownership interest	4.80%
Retained shares of common stock	1,718,972
Common Stock [Member] | BioTime [Member]
Ownership interest	40.20%
Number of shares owned	14,416,000
Common Stock [Member] | BioTime [Member] | Pro Rata Basis [Member]
Number of stock distributed	12,697,028
Juvenescence Limited [Member]
Number of share sold		14,400,000	2,000,000
Sale of stock price per share			$ 2.50
Aggregate cash proceeds from common stock			$ 5,000
Ownership interest		5.60%
Percentage of ownership before transaction		5.60%
Percentage of ownership after transaction		45.80%

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Sep. 30, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Revenues, net		$ 388	$ 239
Deferred revenues		361		$ 317
National Institutes of Health [Member]
Allowable expenses of grant revenues		15
National Institutes of Health [Member] | Maximum [Member]
Revenues, net	$ 225
Subscription and Advertising Revenues [Member]
Revenues, net		$ 345	$ 239

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Ownership of Outstanding Shares of Its Subsidiaries (Details)	3 Months Ended
	Mar. 31, 2019
ReCyte Therapeutics [Member]
Noncontrolling Interest [Line Items]
Field of Business	Early stage pre-clinical research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity
Agex Ownership	94.80%
Country	USA
LifeMap Sciences [Member]
Noncontrolling Interest [Line Items]
Field of Business	Biomedical, gene, and disease databases and tools	[1]
Agex Ownership	81.70%	[1]
Country	USA	[1]
[1]	LifeMap Sciences includes LifeMap Sciences, Inc. and its wholly-owned subsidiary LifeMap Sciences, Ltd. an Israeli company.

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount		2,401,000	1,302,000
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount	[1]		1,474,000
Restricted Stock Units [Member]
Antidilutive securities excluded from computation of earnings per share, amount		12,000
[1]	The warrants were either exercised or expired on March 18, 2019 (see Note 5).

Selected Balance Sheet Compon_3

Selected Balance Sheet Components (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Amortization of intangible assets	$ 139	$ 107

Selected Balance Sheet Compon_4

Selected Balance Sheet Components - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Intangible assets	$ 5,586	$ 5,586
Accumulated amortization	(3,016)	(2,877)
Total intangible assets, net	$ 2,570	$ 2,709

Selected Balance Sheet Compon_5

Selected Balance Sheet Components - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Accounts payable	$ 272	$ 150
Accrued compensation	298	254
Accrued vendors and other expenses	746	962
Total accounts payable and accrued liabilities	$ 1,316	$ 1,366

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 18, 2019	Mar. 23, 2018	Mar. 21, 2018	Oct. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Aug. 17, 2017
Related party payables					$ 140		$ 132
Acquisition of purchase amount						$ 800
Partent Company [Member]
Related party receivables					16		16
Related party payables					34		34
Chief Operating Officer [Member]
Related party payables					$ 156		$ 98
Transactions fixed annual amount				$ 273
Alfred D. Kingsley [Member]
Warrants to purchase common stock	248,600
Warrants exercise price	$ 2.50
Payment of warrants	$ 621,500
Shared Facilities and Service Agreement [Member]
Allocated cost percentage								5.00%
Debt bearing interest rate								15.00%
Asset Contribution Agreement [Member] | In Process Research and Development [Member]
Acquisition of purchase amount			$ 800
Ascendance [Member]
Cash received from related party		$ 3,200
Gain on sale of equity investment						$ 3,200
Close merger cash amount		$ 955

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transactions (Details) - BioTime, Inc [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Total use fees	$ 400	$ 388
Research and Development [Member]
Total use fees	286	318
General and Administrative [Member]
Total use fees	$ 114	$ 70

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Mar. 18, 2019	Jul. 10, 2018	Feb. 28, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Preferred stock, shares authorized				5,000,000		5,000,000
Preferred stock, par value				$ 0.0001		$ 0.0001
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares authorized				100,000,000		100,000,000
Common stock, par value				$ 0.0001		$ 0.0001
Aggregate cash proceed from warrants					$ 737,000
Common stock, shares issued				37,630,000		35,830,000
Common stock, shares outstanding				37,630,000		35,830,000
Warrants [Member]
Sale of warrants purchase of common stock	1,800,000	526,400	1,473,600
Warrants exercise price	$ 2.50	$ 0.50	$ 0.50	$ 2.50
Aggregate cash proceed from warrants	$ 4,500,000	$ 263,200	$ 736,800

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Reconciliation Changes in Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Balance	$ 8,231	$ 8,319
Sale of warrants		737
Stock-based compensation	481	145
Stock-based compensation allocated from BioTime		88
Stock-based compensation in subsidiaries		2
Foreign currency translation adjustment	26	(1)
Net loss	(3,211)	(321)
Issuance of common stock from exercise of warrants	4,500
Balance	10,027	8,969
Common Stock [Member]
Balance	$ 4	$ 3
Balance, shares	35,830,000	33,750,000
Sale of warrants
Stock-based compensation
Stock-based compensation allocated from BioTime
Stock-based compensation in subsidiaries
Foreign currency translation adjustment
Net loss
Issuance of common stock from exercise of warrants
Issuance of common stock from exercise of warrants, shares	1,800,000
Balance	$ 4	$ 3
Balance, shares	37,630,000	33,750,000
Additional Paid-In Capital [Member]
Balance	$ 81,499	$ 73,761
Sale of warrants		737
Stock-based compensation	481	145
Stock-based compensation allocated from BioTime		88
Stock-based compensation in subsidiaries
Foreign currency translation adjustment
Net loss
Issuance of common stock from exercise of warrants	4,500
Balance	86,480	74,731
Accumulated Deficit [Member]
Balance	(74,054)	(66,552)
Sale of warrants
Stock-based compensation
Stock-based compensation allocated from BioTime
Stock-based compensation in subsidiaries
Foreign currency translation adjustment
Net loss	(3,133)	(235)
Issuance of common stock from exercise of warrants
Balance	(77,187)	(66,787)
Noncontrolling Interest [Member]
Balance	784	1,039
Sale of warrants
Stock-based compensation
Stock-based compensation allocated from BioTime
Stock-based compensation in subsidiaries		2
Foreign currency translation adjustment
Net loss	(78)	(86)
Issuance of common stock from exercise of warrants
Balance	706	955
Accumulated Other Comprehensive Income / (Loss) [Member]
Balance	(2)	68
Sale of warrants
Stock-based compensation
Stock-based compensation allocated from BioTime
Stock-based compensation in subsidiaries
Foreign currency translation adjustment	26	(1)
Net loss
Issuance of common stock from exercise of warrants
Balance	$ 24	$ 67

Stock-Based Awards (Details Nar

Stock-Based Awards (Details Narrative) - $ / shares	Mar. 11, 2019	Mar. 31, 2019
Employees, Directors and Consultant [Member]
Number of options to purchase common stock	600,000
Weighted-average estimated fair value of stock options granted	$ 4.28
Restricted Stock Units [Member]
Stock options granted	50,000
2017 Equity Incentive Plan [Member]
Number of common stock reserved		4,000,000

Stock-Based Awards - Summary of

Stock-Based Awards - Summary of Stock Option Activity (Details) - 2017 Equity Incentive Plan [Member]	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, End of the period	4,000,000
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning balance
Number of Options Outstanding, Restricted stock units granted	50,000
Number of Options Outstanding, Options granted
Number of Options Outstanding, Options exercised
Number of Options Outstanding, Options forfeited/cancelled
Number of Options Outstanding, End balance	50,000
Number of Options Outstanding, Exercisable
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Beginning balance	1,731,000
Shares Available for Grant, Restricted Stock Units Granted	(100,000)
Shares Available for Grant, Options Granted	(567,000)
Shares Available for Grant, Options Exercised
Shares Available for Grant, Options Forfeited/Cancelled
Shares Available for Grant, End of the period	1,064,000
Number of Options Outstanding, Beginning balance	2,269,000
Number of Options Outstanding, Restricted stock units granted
Number of Options Outstanding, Options granted	567,000
Number of Options Outstanding, Options exercised
Number of Options Outstanding, Options forfeited/cancelled
Number of Options Outstanding, End balance	2,836,000
Number of Options Outstanding, Exercisable	949,000
Weighted Average Exercise Price of Options Outstanding, beginning balance | $ / shares	$ 2.42
Weighted Average Exercise Price of Options, Restricted stock units granted | $ / shares
Weighted Average Exercise Price of Options, Options granted | $ / shares	4.28
Weighted Average Exercise Price of Options, Options exercised | $ / shares
Weighted Average Exercise Price of Options, Options forfeited | $ / shares
Weighted Average Exercise Price of Options, Outstanding end balance | $ / shares	2.79
Weighted Average Exercise Price of Options, Exercisable | $ / shares	$ 2.22

Stock-Based Awards - Schedule o

Stock-Based Awards - Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Payment Arrangement [Abstract]
Expected life (in years)	5 years 8 months 12 days	6 years 7 days
Risk-free interest rates	2.44%	2.67%
Volatility	78.45%	74.65%
Dividend yield	0.00%	0.00%

Stock-Based Awards - Schedule_2

Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 481	$ 145
Research and Development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	27	51
General and Administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 454	$ 184

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Thousands	Aug. 30, 2018	Mar. 23, 2018	Mar. 31, 2019	Mar. 31, 2018
Gain sale of equity method investment				$ 3,215
LifeMap Sciences [Member]
Repatriation tax foreign earnings in federal income			$ 73
BioTime [Member]
Ownership percentage	40.20%
BioTime [Member] | Maximum [Member]
Ownership percentage	80.40%
Ascendance Biotechnology, Inc. [Member]
Cash received from related party		$ 3,200
Gain sale of equity method investment		3,200
Taxable gain		$ 2,200
Juvenescence Limited [Member]
Sale of common stock	14,400,000
Ownership percentage	5.60%
Juvenescence Limited [Member] | Maximum [Member]
Ownership percentage	45.80%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Mar. 31, 2019USD ($)
Shared Facilities Agreement [Member] | Minimum [Member]
Minimum fixed payments due	$ 133,333

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	May 07, 2019	Apr. 02, 2019USD ($)ft²
Laboratory and Other Equipment [Member]
Payments to acquire equipments on lease		$ 35,000
Lease Agreement [Member]
Area of land | ft²		23,911
Base rent for initial 12 months		$ 35,867
Increase in base rent		$ 36,943
Lease expiration		Dec. 31, 2020
Sublease terminate, description		(a) AgeX fails to pay any rent or any other sum required to be paid under the sublease for a period of ten (10) days after written notice of delinquency is delivered by the sublandlord; provided, however, that if AgeX fails to pay rent or other sums due within ten (10) days of the date due three or more times during any twelve month period, then any subsequent failure to pay any rent or other sum when due shall constitute a default without the requirement of any written notice; (b) a material default by AgeX in the performance of any other terms, covenants or conditions of the sublease where the failure continues for thirty (30) days after written notice from the sublandlord; provided that if AgeX defaults in the performance of the same obligation three or more times in any twelve month period and notice from the sublandlord was given in each instance, no cure period shall thereafter be applicable; (c) AgeX becomes bankrupt or insolvent, makes an assignment for the benefit of creditors, bankruptcy or reorganization proceedings are commenced by or against AgeX, and in the case of an involuntary proceeding are not discharged within 60 days, the appointment of a receiver for a substantial part of AgeX's assets, or the levy upon the sublease or AgeX's estate in the sublease by attachment or execution, or (d) AgeX abandons the New Facility.
Shared Facilities Agreement [Member] | BioTime's Office and Laboratory Facilities [Member]
Agreement termination date	Jul. 31, 2019